non-steroidal anti-inflammatory drugs, variation in inflammatory genes, and aggressive prostate cancer

Clicks: 391
ID: 141930
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #3 of 74 articles by views in journal of cerebral blood flow and metabolism

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Increasing evidence suggests that prostatic inflammation plays a key role in the development of prostate cancer. It remains controversial whether non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of prostate cancer. Here, we investigate how a previously reported inverse association between NSAID use and the risk of aggressive prostate cancer is modulated by variants in several inflammatory genes. We found that NSAIDs may have differential effects on prostate cancer development, depending on one’s genetic makeup. Further study of these inflammatory pathways may clarify the mechanisms through which NSAIDs impact prostate cancer risk.
Reference Key
witte2010pharmaceuticalsnon-steroidal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;John S. Witte;Graham Casey;Iona Cheng;Adam C. Reese;Jill Hardin
Journal journal of cerebral blood flow and metabolism
Year 2010
DOI
10.3390/ph3103127
URL
http://www.mdpi.com/1424-8247/3/10/3127/
Keywords
aspirin genetic variation prostatic neoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.